Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Green Cross Corp. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for blood, over the counter drugs, generals, vaccines, and others. The company was founded on November 1, 1969 and is headquartered in Yongin, South Korea.

Thrombogenics, Inc., a subsidiary of Oxurion NV, is a company headquartered in New York, NY. The firm operates as a biotechnology company engages in delivering innovative treatments for diseases of the back of the eye with a focus on diabetic eye disease.

Corvas International, Inc is develops biotherapeutics that address large medical markets, including cardiovascular disease and cancer.

Karolinska Institutet Innovations AB enables education, professional networking, funding, expertise in entrepreneurship and business development, and incubation opportunities for life science projects and companies. The company was founded in 1996 and is headquartered in Solna, Sweden.

LSI Medience Corp. engages in the clinical examination business. It also engages in the diagnostic agent and drug discovery support business. The company was founded on April 1, 2014 and is headquartered in Tokyo, Japan.

Jiangsu Xiansheng Pharmaceutical Research Co., Ltd., established on 2004-02-10, Business scope includes licensed business items:No general operating items:medical products,Research on medical diagnostic reagents,Technology transfer and related technical consulting services.Self-operated and agent import and export business of various commodities and technologies.*

Imperial Innovations is a technology commercialization and venture capital investor that focuses on technology. Imperial Innovations no longer invests in startups and now functions as the technology-transfer office of Imperial College. Imperial Innovations is focused on commercialising leading UK academic research sourced from the 'golden triangle' formed between Cambridge, Oxford and London. We are a technology commercialisation company that combines the activities of technology transfer, intellectual property protection and licensing, company incubation and investment. Innovations is focused on commercialising the most promising UK academic research across a broad range of technology sectors, and has developed particular expertise in: therapeutics, medtech, engineering and materials and information communication technology.

TTC is located at Burlington. It provides test and analysis products, services, and suppor

Thrombolytic Science is focused on developing a proprietary product, M5, a mutant of pro-urokinase (proUK). M5 is a thrombolytic that follows a different paradigm than tPA, has superior efficacy and is accompanied by little bleeding risk.

CAO Group, Inc. designs, manufactures and sells dental, veterinary, forensic and solid state lighting products. It offers dental products such as whitening gels, desensitizing gels, fluoride gels, pit and fissure sealants, adhesives, soft tissue lasers, light emitting diode curing lights, computer-aided design, computer-aided manufacturing systems, dental materials, delivery tools, dental lab equipment, ultrasonic systems and DENLASER, a soft tissue laser for performing soft tissue surgical procedures. The company was founded by Densen Cao in 2000 and is headquartered in West Jordan, UT.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.

Yakult Honsha Co., Ltd. engages in the manufacture and sale of food and beverage products, cosmetics, and pharmaceuticals. It operates through the following segments: Food and Beverages in Japan, the Americas, Asia and Oceania, and Europe; Pharmaceuticals, and Others. The Food and Beverages segment produces and merchandises milk drinks, noodles, juices, and soft drinks. The Pharmaceuticals segment manufactures and sells anti-cancer drugs and other pharmaceutical products. The Others segment includes cosmetics and professional baseball team management. The company was founded by Minoru Shirota in 1935 and is headquartered in Tokyo, Japan.

Crossbeta Biosciences is a biotech company that has developed an innovative technology to generate stable oligomers for drug discovery and development in disease areas characterized by the presence of misfolded proteins, such as Alzheimer’s, Parkinson’s, Huntington’s disease and ALS. Crossbeta’s unique stable oligomers maintain their biopathological properties for the screening of oligomer-specific therapeutics and for the development of biomarker and diagnostic assays.

CJ Corporation (Korean: 씨제이㈜) is a South Korean conglomerate holding company headquartered in Seoul. It comprises numerous businesses in various industries of food and food service, pharmaceutics and biotechnology, entertainment and media, home shopping and logistics. CJ Group was originally a branch of Samsung until it separated in the 1990s.

The American Red Cross (ARC), also known as the American National Red Cross, is a humanitarian organization that provides emergency assistance, disaster relief, and education inside the United States. It is the designated U.S. affiliate of the International Federation of Red Cross and Red Crescent Societies. It is the largest single supplier of blood and blood products in the United States, collecting and processing approximately 40 percent of the blood supply and distributing it to about 2,600 hospitals and transfusion centers nationwide. The organization researches and tests to protect the safety of the blood supply. It was among the first to develop and implement testing for many infectious diseases including, HIV, hepatitis B and C viruses, West Nile virus, and Chagas disease. The ARC operates the nationwide hemovigilance program to examine donor and patient adverse reactions. Data from the program is used to enhance blood product quality and safety The ARC serves on key committees of AABB and other blood-related organizations, and works closely with the U.S. Food and Drug Administration (FDA). The American Red Cross was established in 1881 and is headquartered in Washington, District of Columbia with 39 immunohematology reference laboratories nationwide.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

The Chemo-Sero Therapeutic Research Institute operates as a pharmaceutical company specializing in the field of biotechnology, immunology, hematology, and microbiology. It develops and manufactures vaccines and blood plasma products. The firm's products include human and veterinary vaccines, diagnostic antigens, and treatments for congenital disorders. They also provides newborn screening tests and quality assurance systems solutions. The company was founded on December 26, 1945 and is headquartered in Kumamoto, Japan.

AstraZeneca is an innovation-driven biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines that are innovative, effective, and which offer added benefits such as reduced side effects or better ways of taking the treatment. AstraZeneca focuses on getting the best from every medicine they make by exploring all the ways it can be used or improved. AstraZeneca was established on April 6, 1999, in Cambridgeshire, United Kingdom.

Part of Novozymes A/S, Delta Biotechnology Ltd. is a company headquartered in Windlesham, UK, that produces and markets a range of valuable proteins from yeast using low cost manufacturing technologies. On July 06, 2006 Novozymes An acquired Delta Biotechnology Ltd.